Kodiak Sciences (KOD) in pivotal point check: Breakthrough in Phase 3 study for ophthalmology – Biotech stock explodes by over 70%!
Reading Time: 2 minutes
Positive GLOW2 study results: Zenkuda (Tarcocimab Tedromer) demonstrates high efficacy in diabetic retinopathy. Massive risk reduction: The drug lowers the risk of severe complications threatening vision by 85%. Accelerated approval process: Kodiak plans to expedite the submission of applications to the FDA due to the strong data. Kodiak Sciences, a biopharmaceutical company specializing in retinal diseases, made headlines on Thursday, March 26, 2026, causing a stir on the Nasdaq. The stock experienced a surge of over 70%, reaching its...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
